Switch theme
Sign up to access all valuation multiples
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
2003
33
Last FY Revenue n/a
LTM EBITDA -$33.0M
$86.2M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Milestone Pharmaceuticals has a last 12-month revenue (LTM) of n/a and a last 12-month EBITDA of -$33.0M.
In the most recent fiscal year, Milestone Pharmaceuticals achieved revenue of n/a and an EBITDA of -$37.8M.
Milestone Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Milestone Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | n/a | XXX | XXX | XXX |
| Gross Profit | -$0.1M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$33.0M | XXX | -$37.8M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBIT | -$50.3M | XXX | -$42.1M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Profit | -$49.5M | XXX | -$41.5M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $28.0M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Milestone Pharmaceuticals's stock price is $2.
Milestone Pharmaceuticals has current market cap of $86.6M, and EV of $86.2M.
See Milestone Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $86.2M | $86.6M | XXX | XXX | XXX | XXX | $-0.70 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Milestone Pharmaceuticals has market cap of $86.6M and EV of $86.2M.
Milestone Pharmaceuticals's trades at 86.2x EV/Revenue multiple, and -2.3x EV/EBITDA.
Equity research analysts estimate Milestone Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Milestone Pharmaceuticals has a P/E ratio of -1.7x.
See valuation multiples for Milestone Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $86.6M | XXX | $86.6M | XXX | XXX | XXX |
| EV (current) | $86.2M | XXX | $86.2M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 86.2x | XXX | XXX | XXX |
| EV/EBITDA | -2.6x | XXX | -2.3x | XXX | XXX | XXX |
| EV/EBIT | -1.7x | XXX | -2.0x | XXX | XXX | XXX |
| EV/Gross Profit | -690.3x | XXX | n/a | XXX | XXX | XXX |
| P/E | -1.7x | XXX | -2.1x | XXX | XXX | XXX |
| EV/FCF | -3.5x | XXX | -3.0x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMilestone Pharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged $1.3M for the same period.
Milestone Pharmaceuticals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Milestone Pharmaceuticals's rule of X is n/a (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Milestone Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Milestone Pharmaceuticals acquired XXX companies to date.
Last acquisition by Milestone Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Milestone Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Milestone Pharmaceuticals founded? | Milestone Pharmaceuticals was founded in 2003. |
| Where is Milestone Pharmaceuticals headquartered? | Milestone Pharmaceuticals is headquartered in United States of America. |
| How many employees does Milestone Pharmaceuticals have? | As of today, Milestone Pharmaceuticals has 33 employees. |
| Who is the CEO of Milestone Pharmaceuticals? | Milestone Pharmaceuticals's CEO is Mr. Joseph G. Oliveto. |
| Is Milestone Pharmaceuticals publicy listed? | Yes, Milestone Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Milestone Pharmaceuticals? | Milestone Pharmaceuticals trades under MIST ticker. |
| When did Milestone Pharmaceuticals go public? | Milestone Pharmaceuticals went public in 2019. |
| Who are competitors of Milestone Pharmaceuticals? | Similar companies to Milestone Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Milestone Pharmaceuticals? | Milestone Pharmaceuticals's current market cap is $86.6M |
| Is Milestone Pharmaceuticals profitable? | Yes, Milestone Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Milestone Pharmaceuticals? | Milestone Pharmaceuticals's last 12 months EBITDA is -$33.0M. |
| What is the current EV/EBITDA multiple of Milestone Pharmaceuticals? | Current EBITDA multiple of Milestone Pharmaceuticals is -2.6x. |
| What is the current FCF of Milestone Pharmaceuticals? | Milestone Pharmaceuticals's last 12 months FCF is -$24.5M. |
| What is the current EV/FCF multiple of Milestone Pharmaceuticals? | Current FCF multiple of Milestone Pharmaceuticals is -3.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
